American Century Companies Inc. Increases Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• American Century Companies Inc. increased its stake in Alnylam Pharmaceuticals by 9.8%, owning approximately 1.35% of the company worth $475.4 million after acquiring 156,411 additional shares in the first quarter.
• CEO Yvonne Greenstreet sold 19,297 shares at an average price of $306.00, resulting in a transaction total of nearly $5.9 million, reducing her holdings by 28.28%.
• Analysts have set a consensus rating of "Moderate Buy" on Alnylam Pharmaceuticals, with an average target price of $403.92, reflecting strong confidence in the company's future performance.

American Century Companies Inc. boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 9.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,760,435 shares of the biopharmaceutical company's stock after purchasing an additional 156,411 shares during the quarter. American Century Companies Inc. owned approximately 1.35% of Alnylam Pharmaceuticals worth $475,353,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Whipplewood Advisors LLC increased its holdings in Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 71 shares during the period. Bessemer Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 69 shares during the last quarter. Park Square Financial Group LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $28,000. Colonial Trust Co SC purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $35,000. Finally, Washington Trust Advisors Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 53.5% in the 1st quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 61 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Price Performance

ALNY stock traded up $7.96 during midday trading on Monday, hitting $456.87. 1,608,807 shares of the stock were exchanged, compared to its average volume of 1,321,450. The stock's 50-day moving average price is $348.15 and its 200-day moving average price is $291.81. The stock has a market cap of $59.89 billion, a price-to-earnings ratio of -184.97 and a beta of 0.25. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $457.92. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.86. The firm had revenue of $773,689 billion during the quarter, compared to analysts' expectations of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%. Alnylam Pharmaceuticals's revenue was up 17.3% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.13) earnings per share. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ALNY. Truist Financial started coverage on Alnylam Pharmaceuticals in a report on Monday, July 21st. They issued a "buy" rating and a $385.00 price objective on the stock. Scotiabank raised their price target on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the stock a "sector outperform" rating in a research note on Friday, August 1st. Wells Fargo & Company raised their price target on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the stock an "equal weight" rating in a research note on Friday, August 1st. Wall Street Zen upgraded Alnylam Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Finally, Morgan Stanley increased their price objective on Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the stock an "equal weight" rating in a research report on Friday, August 1st. Four investment analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $405.33.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 31,640 shares of the firm's stock in a transaction on Friday, May 30th. The stock was sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the completion of the transaction, the chief executive officer owned 48,948 shares of the company's stock, valued at approximately $14,899,281.72. This trade represents a 39.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Dennis A. Ausiello sold 31,448 shares of the firm's stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $436.58, for a total value of $13,729,567.84. Following the transaction, the director directly owned 911 shares of the company's stock, valued at $397,724.38. The trade was a 97.18% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 82,385 shares of company stock valued at $29,265,349 in the last three months. 1.20% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.